Cervarix, a bivalent HPV vaccine to prevent cervical cancer

Cervarix, a bivalent vaccine against HPV‐16 and ‐18, is licensed for the prevention of cervical cancer and has been chosen for the HPV immunisation programme. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Mr Nick Nicholas comments on its place in HPV protection. Copyright © 2008 Wiley Interface Ltd